Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This study will further characterize the activity of Tositumomab and Iodine I 131-Tositumomab
in patients with relapsed indolent non-Hodgkin's Lymphoma who have progressed following
treatment with rituximab.